BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05695950 (GLPG3667 in Dermatomyositis): BVCT ex-ante prediction vs. reported outcome

On 17 Nov 2025, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 18 Dec 2025 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05695950
Acronym
GALARISSO
Drug Name
GLPG3667
Drug MoA
selective TYK2 inhibitor
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Skin and Connective Tissue Diseases
Indication
Dermatomyositis
Human Patients
40
Sponsor
Galapagos
Phase
Phase 2

Prediction of , index 2097

Prospective Prediction
Prediction Index
2097
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient (additive) clinical benefit in TIS score)
Technical Prediction
FAILURE (statistically insignificant (additive) clinical benefit in TIS score compared with placebo)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
31 days in advance
Readout Data Interpretation
GLPG3667 achieved statistically insignificant placebo-adjusted TIS improvement at week 24 (p=0.085 per phase 3 standard), statistically insignificant placebo-adjusted TIS20, TIS40, TIS60 and m-CDASI-A
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis
Phase
Phase 2
Status
Completed
Enrollment
40
Lead sponsor
Lakefront Biotherapeutics NV
Conditions
Dermatomyositis
Interventions
DRUG: GLPG3667; DRUG: Placebo
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2023-02-27
Primary completion
2025-10-13
Completion
2026-04-20
Primary outcomes
  • Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria (Week 24)

NCT05695950 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials